Optimize cancer care earlier through ctDNA monitoring.

Circulating tumor DNA (ctDNA) is the key to dynamic, minimally invasive cancer monitoring at all stages.1

*Median turnaround time from sample receipt to results.

CRC, colorectal cancer; OS, overall survival; PFS, progression-free survival.

Important note: Guardant Reveal and Guardant360 Response were developed as Laboratory Developed Tests (LDTs), and their performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These tests have not been cleared or approved by the US FDA.

References: 1. Kasi PM, Fehringer G, Taniguchi H, et al. Impact of circulating tumor DNA-based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors. JCO Precis Oncol. 2022;6:e2100181. doi:10.1200/PO.21.00181 2. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586-5594. doi:10.1158/1078-0432.CCR-21-0410 3. Nakamura Y, Tsukada Y, Matsuhashi N, et al. Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay. Clin Cancer Res. 2024;30(19):4377-4387. doi:10.1158/1078-0432.CCR-24-1651 4. Yang Y, Lu Y, Tan H, et al. The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer. BMC Cancer. 2023;23(1):422. doi:10.1186/s12885-023-10863-w 5. Guardant Health data on file. September 27, 2024. Guardant Health, Inc. Redwood City, CA. 6. Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26(8):1715-1722. doi:10.1093/annonc/mdv177 7. Lavacchi D, Gelmini S, Calabri A, et al. Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients. Heliyon. 2023;9(11):e21853. doi:10.1016/j.heliyon.2023.e21853 8. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853. doi:10.1158/2159-8290.CD-20-0047 9. Thompson JC, Carpenter EL, Silva BA, et al. Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy. JCO Precis Oncol. 2021;5:510-524. doi:10.1200/PO.20.00321 10. Matsubara J, Mukai K, Kondo T, et al. First-line genomic profiling in previously untreated advanced solid tumors for identification of targeted therapy opportunities. JAMA Netw Open. 2023;6(7):e2323336. doi:10.1001/jamanetworkopen.2023.23336